Diagnose and Treat Lassa Fever Video Training: Information for Medical Providers
Learn to diagnose and treat Lassa fever
While viral hemorrhagic fevers (VHFs), like Lassa fever, are very serious, they are not common in the U.S. However, it is important for healthcare providers to understand high consequence viruses, like Lassa fever, so they can appropriately diagnose and care for their patients. This video is the second in a two-part training series on Lassa fever for healthcare providers. It focuses on methods for diagnosing Lassa fever and infection control measures to consider while caring for a patient with Lassa fever. Participants will learn about treatment options, as well as post-exposure prophylaxis (PEP).
What you will learn
- Describe at least two methods for identifying a patient with Lassa fever infection in the clinical setting.
- Describe at least two infection control recommendations when caring for a Lassa fever patient.
- Identify the parameters for clinical management of patients with Lassa fever.
- Describe post-exposure prophylaxis (PEP) for Lassa fever.
- Describe my role, responsibility, and scope of practice as a team member in diagnosing and treating patients with Lassa fever.
In order to receive continuing education (CE) for WD4187 – Diagnose and Treat Lassa Fever: Information for Medical Providers, please visit TCEO and follow these 9 Simple Steps before February 1, 2023.
- Complete the activity.
- Complete the Evaluation at www.cdc.gov/GetCE
- Pass the posttest at 75% at www.cdc.gov/GetCE
FEES: No fees are charged for CDC’s CE activities.
In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention designates this activity for 0.3 nursing contact hours.
DISCLOSURE: In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.
CDC, our planners, content experts, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Aaron Kofman’s discussion of ribavirin, favipiravir and monoclonal antibodies. He will discuss summative clinical evidence to date for the use of these drugs for the treatment of Lassa fever. He will not provide original data on these topics.
CDC did not accept commercial support for this continuing education activity.